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Abstract: In this study we set out to define the characteristics of autonomic subgroups of patients
with Chronic Fatigue Syndrome (CFS). The study included 131 patients with CFS (Fukuda criteria).
Participants completed the following screening symptom assessment tools: Chalder Fatigue Scale,
Fatigue Impact Scale, Fatigue Severity Scale, Epworth Sleepiness Scales, the self-reported Composite
Autonomic Symptom Scale. Autonomic parameters were measured at rest with a Task Force Monitor
(CNS Systems) and arterial stiffness using an Arteriograph (TensioMed Kft.). Principal axis factor
analysis yielded four factors: fatigue, subjective and objective autonomic dysfunction and arterial
stiffness. Using cluster analyses, these factors were grouped in four autonomic profiles: 34% of
patients had sympathetic symptoms with dysautonomia, 5% sympathetic alone, 21% parasympathetic
and 40% had issues with sympathovagal balance. Those with a sympathetic-dysautonomia phenotype
were associated with more severe disease, reported greater subjective autonomic symptoms with
sympathetic over-modulation and had the lowest quality of life. The highest quality of life was observed
in the balance subtype where subjects were the youngest, had lower levels of fatigue and the lowest
values for arterial stiffness. Future studies will aim to design autonomic profile-specific treatment
interventions to determine links between autonomic phenotypes CFS and a specific treatment.
Keywords: autonomic; chronic fatigue; quality of life
1. Introduction
Chronic Fatigue Syndrome (CFS) is a multi-system complex disorder, characterized by extreme
mental and physical fatigue with an array of physical symptoms not relieved by rest. Additional
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core symptoms include post-exertional malaise, sleep disturbance, cognitive abnormalities including
memory loss, poor concentration and a general reduction in cognitive ability. Over the last 20 years
a variety of hypotheses have been proposed, to explain the complex etiology, including disruptions
in mitochondrial, metabolic, immunological, virological, neuroendocrinological and psychological
function [1]. To date there is conflicting evidence for these hypotheses with no clear evidence to
support any one area as a major player. Data are emerging that biological differences are found in CFS
when compared to controls. However, it remains to be proven that these are not just a consequence
of inactivity and we need to start to link the biological differences to the clinical phenotype if we
are to make real progress in understanding the causes of the condition. It has been suggested that
deregulation of stress-responsive systems: hypothalamic-pituitary-adrenal axis, autonomic nervous
system and immune system contributes to the core symptoms of CFS [2]. Autonomic imbalance
has been frequently reported in patients with CFS, with symptoms including dysautonomia with
orthostatic hypotonia, postural orthostatic tachycardia syndrome and gastro-intestinal disturbances
being important components [3]. CSF can include sympathetic hyperactivation or parasympathetic
dysfunction—fatigue, unrefreshing sleep, cognitive disturbance, post-exertional malaise could all link
to this autonomic dysfunction [4].
In the present study we set out to define the characteristics of an autonomic subgroups of patients
with CFS. It was hypothesized that fatigue severity was different in relation to autonomic function
in patients with CFS. Identifying autonomic symptomatology in individuals with CFS will further
contribute to the understanding of the role that the autonomic nervous system plays in CFS and could
be useful in targeting specific treatments that will be not only effective in fatigue reduction but will be
regarding to quality of life and self-perceived changes in overall health.
2. Experimental Section
2.1. Participants
The study included 131 patients with CFS who met Fukuda criteria. Participants were recruited
via e-mail, telephone and mass-media advertisements. Apart from giving their written informed
consent to participation in the study, the main enrolment criteria included (1) age between 25 and
65 years, (2) fatigued for more than 6 months, with a score of >36 on the Fatigue Severity Scale, (3) had
at least four of additional symptoms: post-exertional malaise, headache, impaired memory and/or
concentration, unrefreshing sleep, sore throat, tender lymph nodes (cervical or axillary), muscle or
joint pain, (4) the fatigue must not be the result of an organic disease (i.e., psychiatric/neurological
disorders (depression, anxiety, fibromyalgia, sleep disorders), neurodegenerative disorders, infectious
diseases (herpes simplex virus, enterovirus, Lyme disease, Q fever, Borna disease virus), endocrine
disease (hypothyroidism, diabetes mellitus, severe obesity) or immunologic disorders (lupus, multiple
sclerosis, temporomandibular joint disorders)). All subjects were instructed to refrain from smoking,
caffeine, alcohol ingestion and intensive physical activity on the day of investigation and ate a light
breakfast only. All investigations were performed at approximately the same time of day, and took
place at the chronobiology laboratory (windowless and sound-insulated room, temperature 22 ◦C,
humidity 60%). CFS patients could participate in this study if they fulfilled the eligibility criteria for
Centers for Disease Control and Prevention (Fukuda) and had been referred by a general practitioner
and by the neurology and psychiatry departments. Pre-test health state assessment of subjects included:
basic neurological, psychiatric, clinical examination and satisfying the above four checks. Where there
was any indication of underlying illness, the patient was referred to a specialist in internal medicine,
neurology or psychiatry for further investigation. An interview with a psychiatrist was scheduled if the
Hospital Anxiety and Depression Scale (HADS) depression subscale score was 11 or more (to exclude
a major or bipolar depressive disorder) or if the consultant suspected another psychiatric illness.
This study took place between January 2013 to July 2018 and it was approved by the Ethics
Committee, Ludwik Rydygier Memorial Collegium Medicum in Bydgoszcz, Nicolaus Copernicus
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University, Torun´ (KB 332/2013, date of approval: 25 June 2013); written informed consent was obtained
from all of the participants.
2.2. Measures
Fatigue severity was assessed with the Chalder Fatigue Scale (CFQ), Fatigue Impact Scale (FIS)
and Fatigue Severity Scale (FSS).
The Chalder Fatigue Scale consists of 11 items loading onto two dimensions of fatigue severity—
mental fatigue and physical fatigue. Seven items represent physical fatigue (items 1–7) and four
represent mental fatigue (items 8–11). This scale was scored in “Likert” style asking individuals 0, 1,
2 and 3 with a range from 0 to 33. Mean “Likert” score was 24.4 (SD 5.8) and 14.2 (SD 4.6) [5].
The Fatigue Impact Scale (FIS) assesses the impact that subjective fatigue has on daily functioning [6].
Forty items are each scored on a five-point Likert scale (0–4) providing a continuous scale of 0–160
with a higher score indicating greater impact [6].
The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue. The FSS is a
short questionnaire that requires rating of the level of fatigue. The FSS questionnaire contains nine
statements that rate the severity of your fatigue symptoms on a scale of 1 to 7, based on how accurately
it reflects the condition during the past week. A low value (e.g., 1) indicates strong disagreement with
the statement, whereas a high value (e.g., 7) indicates strong agreement. A total score of less than
36 suggests no fatigue. A total score of 36 or more suggests fatigue [7].
In view of the association between excessive daytime sleepiness and fatigue, all subjects completed
the Epworth Sleepiness Scale (ESS, possible score range 0–24). This fully validated tool assesses
daytime hypersomnolence, with a score ≥10 being indicative of significant hypersomnolence during
the day [8].
Moreover, subjects completed the Orthostatic Grading Scale (OGS), a fully validated self-reported
tool to assess the symptoms of orthostatic intolerance due to orthostatic hypotension (e.g., severity,
frequency and interference with daily activities). The OGS consists of five items, each graded on a
scale of 0–4; adding the scores for the individual items creates a total score of 0–20. Scores of greater or
equal to 4 are considered to be consistent with orthostatic intolerance and scores greater or equal to
9 orthostatic hypotension [9].
Participants also completed the Quality of Life Scale (QOLS), which has 16 items. The QOLS
is scored by adding up the score on each item to yield a total score for the instrument. Scores can
range from 16 to 112. There is no automated administration or scoring software for the QOLS. Higher
scores indicate a better quality of life. The average total for healthy populations is approximately
90. The QOLS has been used in studies of healthy adults and patients with rheumatic diseases,
fibromyalgia, chronic obstructive pulmonary disease, gastrointestinal disorders, cardiac disease, spinal
cord injury, psoriasis, urinary stress incontinence, posttraumatic stress disorder and diabetes [10].
Autonomic symptoms were measured using subjective and objective tools. First, participants
completed the Autonomic Symptom Profile [11] as a self-report measure of autonomic symptoms.
However, scoring was performed according to the recently abbreviated and psychometrically improved
version of this questionnaire, the Composite Autonomic Symptom Score 31 (COMPASS 31) [12].
Scoring consists of 31 items from six domains—orthostatic intolerance, vasomotor, secretomotor,
gastrointestinal, bladder and pupillomotor—each weighted according to the number of items and
clinical relevance. Weighted individual domain scores are totaled to a maximum of 100, which indicates
greater symptom load.
Moreover, autonomic parameters (Table 1) were automatically measured at rest (15 min after
stabilization of the signals) with a dedicated high-tech device Task Force Monitor—TFM (CNS Systems,
Gratz, Austria). The integrity of the autonomic nervous system was assessed using a three-channel
ECG and continuous blood pressure monitoring (contBP with periodically cross-checked oscillometric
blood pressure measurements). TFM automatically provides a power spectral analysis for heart rate
variability (HRV) and blood pressure variability (BPV). HRV and BPV spectral analysis is conducted
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using the adaptive autoregressive model proposed by Bianchi et al. Because of the characteristics of
the adaptive autoregressive model, which may produce outliers when analyzing R-wave to R-wave,
all HR beat-to-beat data were filtered using Grubbs’s test for outliers’ elimination. This method of
filtering is well-documented and has a strong mathematical background [13].
Table 1. Autonomic parameters.
Sympathetic Modulation Parasympathetic Modulation
LF-RRI [ms2] HF-RRI [ms2]
LFnu-RRI [%] HFnu-RRI [%]
LF-sBP [mmHg2] HF-sBP [mmHg2]
LFnu-sBP [%] HFnu-sBP [%]
LF-dBP [mmHg2] HF-dBP [mmHg2]
LFnu-dBP [%] HFnu-dBP [%]
LF, low frequency. HF, high frequency. LFnu, HFnu, frequencies calculated in normalized units. RRI, R-R interval.
sBP, systolic blood pressure. dBP, diastolic blood pressure.
A high frequency band (HF) was defined as frequencies 0.15–0.4 Hz and a low frequency band
(LF) as 0.04–0.15 Hz. These variability indices reflect autonomic control, with greater HF values
reflecting greater vagal (parasympathetic) modulation and higher LF values indicating predominantly
sympathetic modulation. Using only HRV bands when considering autonomic regulation has some
limitations, therefore, TFM also provides spectral analysis of blood pressure variability, a more reliable
tool for sympathetic and parasympathetic autoregulation assessment [14,15].
Arterial stiffness was measured using an Arteriograph (TensioMed Kft., Budapest, Hungary,
www.tensiomed.com). This device uses a simple upper arm cuff as a sensor with the cuff pressurized to
at least 35 mmHg over the actual systolic pressure. Small supra-systolic pressure changes are recorded
by a high-fidelity pressure sensor in the device. In this situation the conduit arteries (subclavian,
axillary, brachial) act like a cannula to transfer the central pressure changes to the edge-position sensor
(similar to the central pressure measurement during cardiac catheterization). The Arteriograph first
measures the actual systolic and diastolic blood pressures (BPs) oscillometrically, then the device
decompresses the cuff. In a few seconds the device starts inflating the cuff again, first to the actually
measured diastolic pressure, then to the suprasystolic (actually measured systolic þ35 mmHg) pressure,
and records the signals for 8 s (optionally up to 10) at both cuff pressure levels. All of the signals
received by the device are transmitted to a PC. The software of the device determines the augmentation
index according to the manufacturer’s instructions. To determine the aortic pulse wave velocity
(PWVao), the Arteriograph uses the physiological behavior of the wave reflection, namely that the
ejected direct (first systolic) pulse wave is reflected back mostly from the aortic bifurcation [16,17].
2.3. Statistical Analyses
Analyses were performed using SPSS for Mac version 20.0 (IBM, Armonk, NY, USA) and the level
of significance was set at p < 0.05. The fatigue, anxiety, depression, autonomic scale scores and arterial
stiffness and autonomic parameters were used as input in a higher-order principal axis factor analysis
with oblimin rotation to reduce the number of variables. Criteria used for excluding variables in the
factor analysis were a factor loading of <0.40 or a loading of >0.32 on at least two factors. The decision
about the number of factors was based on inspection of the scree plot [18] and heuristic interpretability
of the factors [19]. Standardized z-scores [(value-mean)/standard deviation (SD)] were computed for
the score of each participant in each variable using the mean and SD of the total sample. Internal
consistency of factors was analyzed by Cronbach’s α.
Identification of the profiles in CFS patients consisted of two steps. First, hierarchical cluster
analysis with Ward’s method was conducted to identify the optimal number of clusters (profiles),
which was decided by heuristic interpretability of the clusters [20,21]. Next, a k-means cluster analysis
was performed to allocate participants to clusters. Profiles were characterized by averaging z-scores of
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variables included in a same factor. Factor scores of participants with missing data were computed
(averaging by the number of variables with no missing data) if their data were available at least 50% of
the variables. Differences between profiles (independent variable) in categorical and continuous data
(dependent variables) were analyzed by a series of χ2 test or one-way analysis of variance (ANOVA).
Significance of χ2 test was based on the z-score of the difference between observed and expected
frequency; a z-score >|1.96| was considered significant [22]. Within the subsample of participants who
filled out the quality of life questionnaire, an independent t-test was conducted to compare the scores
of the two profiles with the highest and the lowest levels of quality of life. ANOVA was not considered
due to the reduced sample size of participants with scores on quality of life. Cohen’s d (standardized
mean differences) values were interpreted as small (0.2), medium (0.5) or large (0.8) effects. Multivariate
linear regression was performed to predict PWVaortic, Aixaortic and SBPaortic values (indicators of
aortic stiffness) by single CFQ questions. Moreover, relationships between indicators of aortic stiffness
with FIS and FSSscores were assessed. To assess the models, multivariate R2 and adjusted R2 are
reported with p-values (denoted as Total).
3. Results
3.1. Whole Study Group Analysis
From the initial 131 interested participants, 29 were excluded as they did not meet the Fukuda
criteria (n = 9), had an underlying psychiatric illness (n = 13), had another diagnosis or fatigue was not
the primary complain (n = 7). Of the total group with CFS (n = 102), 66 were female (64.7%), mean age
was 38.1±8.0 years and years since first episode of fatigue 4.5 ± 4.1 years. The vast majority described
impaired short-term memory and concentration 90.2%, unrefreshing sleep 84.3%, post-exertional
malaise 80.4%, multi-joint pain without swelling or redness 78.4%, muscle pain 61.8%, headaches
56.9%, sore throat 44.1% and tender cervical or axillary lymph nodes 28.4%. Fatigue scores assessed
were 48.1 ± 8.8 using the Fatigue Severity Scale, 80.9 ± 30.0 using the Fatigue Impact Scale, 24.1 ± 4.3
using the Chalder Fatigue Scale (total), 10.5 ± 3.9 using the Chalder Fatigue Scale physical domain and
9.0 ± 1.9 using the Chalder Fatigue Scale mental domain (mean results for all individual questions
of Chalder Fatigue Scale and mean results of Fatigue Severity Scale and Fatigue Impact Scale, for all
participants, are available in Supplementary file 1). Table 2 shows detailed information about the total
group with CFS.
Table 2. Detailed clinical characteristics of all patients with Chronic Fatigue Syndrome (CFS).
Parameters
CFS Group
Mean SD
COMPASS 31
Orthostatic intolerance 11.8 11.0
Vasomotor 0.8 1.4
Secretomotor 5.5 3.9
Gastrointestinal 5.1 4.2
Bladder 0.6 0.9
Pupillomotor 1.1 1.2
CompassTotal 25.0 14.7
Arterial stiffness
PWVaortic 8.4 1.7
Aixaortic 28.9 14.6
SBPaortic 130.0 17.0
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Table 2. Cont.
Parameters
CFS Group
Mean SD
Autonomic parameters
LFnu-RRI 54.9 16.6
HFnu-RRI 45.1 16.6
LF-RRI 602.6 769.6
HF-RRI 520.4 731.4
LFnu-dBP 52.0 14.7
HFnu-dBP 12.9 9.8
LF-dBP 6.7 9.1
HF-dBP 1.4 2.2
LFnu-sBP 42.1 14.0
HFnu-sBP 15.5 10.3
LF-sBP 7.8 9.9
HF-sBP 2.5 3.6
Tables 3 and 4 show results of multivariate linear regression analysis between the mental and
physical domain of the Chalder Fatigue Scale, Fatigue Severity Scale, Fatigue Impact Scale and
indicators of aortic stiffness.
Table 3. Relationship between results of mental and physical fatigue from the CFQ scale and
arteriography in linear regression analysis.
PWVaortic Aixaortic SBPaortic
Beta p R2 Beta p R2 Beta p R2
CFQ_physical −0.06 0.56 0.4 0.05 0.65 0.4 0.08 0.43 0.4
CFQ_mental −0.23 0.02 0.4 0.05 0.65 0.4 −0.08 0.44 0.4
Total * 0.07 0.05 (0.03) 0.84 0.00 (−0.02) 0.47 0.02 (0.00)
* Total denotes results of linear regression model (p value and multiple R2 (adjusted R2).
Table 4. Relationship between results of FSS and FIS and arterial stiffness parameters in the linear
regression analysis.
PWVaortic Aixaortic SBPaortic
Beta p R2 Beta p R2 Beta p R2
FSS 0.14 0.26 0.4 0.23 0.07 0.4 0.29 0.02 0.4
FIS −0.33 0.01 0.4 −0.19 0.14 0.4 −0.31 0.02 0.4
Total * 0.03 0.07 (0.05) 0.18 0.03 (0.01) 0.04 0.07 (0.05)
* Total denotes results of linear regression model (p value and multiple R2 (adjusted R2).
Multivariate linear regression analysis between single questions from Chalder Fatigue and
indicators of aortic stiffness are available in Supplementary file 2).
3.2. Cluster Analysis
Exploratory factor analysis was conducted to reduce the number of variables by clustering them into
a reduced number of factors. Most of the assumptions for this analysis were met. However, a number
of variables related to autonomic nervous system functioning showed skewed distributions (skewness
>2 [22]): power spectral density (PSD) of HRV and BPV, LF-RRI, HF-RRI, LF/HF-RRI, LF/HF_RRI,
HFnu-dBP, LF-dBP, HF-dBP, LF/HF-dBP, HFnu-sBP, HF-sBP and LF/HF_sBP. Data transformations did
not solve this skew, and consequently, these variables were not included in the factor analysis because
the factor analysis requires variables to have roughly normal score distributions. The inputs of the factor
analysis are the correlations between the variables. Thus, when multicollinearity, r >|0.80| [22], between
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pairs of the variables were observed, one of the variables was excluded (namely, the HFnu-RRI). Factor
analysis showed sampling adequacy; Kaiser-Meyer-Olkin = 0.6 [22]. The Barlett’s test of sphericity
was significant (χ2 = 939.2, p < 0.001), which indicated that variables were (overall) significantly
correlated [20]. Therefore, our factor analysis was appropriate.
The scree plot suggested a solution between two and eight factors. The four-factor solution was
considered the best solution because it was the easiest to interpret by the research team (e.g., to name
each of the emerging factors). The following variables were not included in the factor solution
because their factor loadings were either <0.40 on all factors (i.e., the contribution to the factors was
not substantial) or >0.32 on, at least, two factors (i.e., a variable substantially contributed several
factors) [18]: Vasomotor (COMPASS), Bladder (COMPASS), HFnu-sBP and LF/HF-sBP (all from
objectively measured autonomic nervous system). Table 5 shows the remaining 19 variables that were
included in the four factors and the appropriateness of internal consistency of these factors (for all,
Cronbach’s α ≥ 0.7).
Table 5. Factors emerged from higher-order principal axis factor analysis, n = 102.
Factor Cronbach’s α Scales/Measurements
Fatigue 0.86 Chalder Fatigue Scale, mental domain (CFQ), FatigueSeverity Scale and Fatigue Impact Scale
Subjective autonomic function 0.73
Chalder Fatigue Scale—physical domain (CFQ),
Epworth Sleepiness Scale (ESS), Orthostatic Grading
Scale (OGS, total score), orthostatic intolerance
(COMPASS), secretomotor (COMPASS), gastrointestinal
(COMPASS) and pupilomotor (COMPASS)
Objective autonomic function 0.68 LFnu-RRI, LFnu-dBP and LFnu-sBP (all, Task ForceMonitor—TFM, CNS Systems, Gratz, Austria)
Arterial stiffness 0.76
Aortic pulse wave velocity (PWVaortic), augmentation
index (Aixaortic) and central blood pressure (SBPaortic);
(all, Arteriograph, TensioMed Budapest, Hungary)
Within each factor, scales/measurements are described in order of their factor loadings. CFQ, Chalder Fatigue Scale;
COMPASS, Composite Autonomic Symptom Score 31; FIS, Fatigue Impact Scale; FSS, Fatigue Severity Scale; OGS,
Orthostatic Grading Scale.
Cluster analysis suggested a four-cluster solution. We named each cluster into sympathetic or
parasympathetic dominant according to their sympathovagal balance during the 15 min of supine
rest. This was based on previous studies and assessed using the LF/HF ratio, which was considered to
suggest a sympathetic dominant pattern if LF/HF was >1 and parasympathetic if the ratio was <1 [23].
Cluster 1: Sympathetic with dysautonomia profile (LF/HF = 1.8, n = 35, 34%), Cluster 2: Sympathetic
profile (LF/HF = 1.5, n = 5, 5%), Cluster 3: Parasympathetic profile (LF/HF = 0.7, n = 21, 21%) and
Cluster 4: Balanced (LF/HF = 1, n = 41, 40%). Table 6 shows the characteristics of the 102 participants
included in the present study (detailed information about each profile are available in Appendix A,
Table A1).
Table 6. Sociodemographic and clinical characteristics of each profile.
Sympathetic
with ANS
Symptoms
Sympathetic Parasympathetic Balanced
(n = 35) (n = 5) (n = 21) (n = 41)
Mean SD Mean SD Mean SD Mean SD
Age (years old) 38.6 7.8 46.0 4.6 39.6 7.9 35.8 7.9
Years since first
episode of fatigue 5.7 4.9 3.1 2.1 4.7 4.7 3.8 3.2
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Table 6. Cont.
Sympathetic
with ANS
Symptoms
Sympathetic Parasympathetic Balanced
(n = 35) (n = 5) (n = 21) (n = 41)
Mean SD Mean SD Mean SD Mean SD
Questionnaire scores
Chalder Fatigue Scale 25.6 4.3 18.0 3.4 26.2 3.5 21.6 3.6
Chalder Fatigue
Scale_mental domain 9.9 1.5 7.2 2.5 9.8 1.2 7.9 1.9
Chalder Fatigue
Scale_physical domain 11.2 4.5 7.8 2.7 9.9 3.3 7.9 1.9
Fatigue Impact Scale 94.3 23.5 34.2 21.7 99.2 23.5 58.4 25.5
Fatigue Severity Scale 51.4 6.0 39.2 7.6 54.0 6.5 40.4 10.5
n % n % n % n %
Gender, Women, n (%) 19 54.3 5 100 17 81 25 62.5
Education level
Lower than secondary 1 2.9 0 0 1 4.8 2 5
Secondary 8 22.9 3 60 4 19 9 22.5
University 26 74.3 2 40 16 76.2 29 72.5
Current job
Unemployed/Student 3 8.6 0 0 1 4.8 2 5
Physical work 7 20 1 20 4 19 9 22.5
Technician/Engineer 2 5.7 0 0 1 4.8 4 10
Management/Headquarters 1 2.9 0 0 5 23.8 3 7.5
Specialist/Independent
profession 22 62.9 4 80 10 47.6 22 55
SD, Standard Deviation. ANS, Autonomous Nervous System.
Participants in the Balanced and in the Sympathetic profiles were the youngest and oldest,
respectively (p = 0.03). There were no differences between profiles for gender, years since first episode
of fatigue, education level and current job (p-values ranging from 0.07 for gender to 0.65 for education
level). Table 7 shows that collectively the profiles were similar in Fukuda characteristics, with only
one exception: post-exertional malaise more than 24 h was more common in the Sympathetic with
dysautonomia (p = 0.02).
Table 7. Clinical characteristics of all the participants and of each profile according to the Fukuda criteria.
Sympathetic with
Dysautonomia Sympathetic Parasympathetic Balanced
(n = 35) (n = 5) (n = 21) (n = 41)
n % n % n % n %
Post-exertional malaise
(more than 24 h) 34 97.1 4 80 14 66.7 30 73.2
Unrefreshing sleep 32 91.4 4 80 19 90.5 31 75.6
Impairment in short-term
memory or concentration 35 100 4 80 18 85.7 35 85.4
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Table 7. Cont.
Sympathetic with
Dysautonomia Sympathetic Parasympathetic Balanced
(n = 35) (n = 5) (n = 21) (n = 41)
n % n % n % n %
Muscle pain 25 71.4 5 100 15 71.4 18 43.9
Multi-joint pain without
swelling or redness 26 74.3 5 100 15 71.4 34 82.9
Headaches of a new type
(pattern or severity) 20 57.1 1 20 15 71.4 22 53.7
Sore throat 21 60.0 1 20 10 47.6 13 31.7
Tender lymph nodes 10 28.6 0 0 8 38.1 11 26.8
Figure 1 illustrates the mean factor scores at the five profiles, of which the scores are compared in
Table 8.
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Table 8. Differences in factors between subgroups, n = 102.
Factors # Post-hoc Differences Testing F (3, 98) p
Fatigue Parasympathetic, Sympathetic withdysautonomia > Balanced, Sympathetic 32.57 <0.001
Subjective autonomic function Sympathetic with dysautonomia > Balanced,Parasympathetic, Sympathetic 6.40 0.001
Objective autonomic function Sympathetic with dysautonomia, Sympathetic
> Balanced > Parasympathetic 33.57 <0.001
Arteriography Sympathetic > Parasympathetic > Sympatheticwith dysautonomia, Balanced 30.63 <0.001
# Post-hoc differences were tested by Student-Newman-Keuls.
J. Clin. Med. 2020, 9, 2531 10 of 15
The Sympathetic with dysautonomia profile showed high both fatigue and (subjective and
objective) autonomic function and low value of arterial stiffness parameters. The Sympathetic profile
was characterized by markedly low value of fatigue and subjective autonomic function, high value
of objective autonomic function and markedly high value of arteriography. The Parasympathetic
profile showed high values of fatigue, average subjective autonomic function, low objective autonomic
function and high arterial stiffness. The Balanced profile had low values of fatigue, objective autonomic
function and arteriography and average subjective autonomic function.
ANOVA showed that profiles were significantly different in quality of life; F(3, 61) = 2.98, p = 0.04.
Figure 2 illustrates post-hoc comparisons between profiles.
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Figure 2. Quality of life in each profile (mean ± 95% Confidence interval, n = 65). One-way analysis of
variance; common asterisk indicates significant differences between profiles in post-hoc comparisons.
The analyses wer not corrected for multiple comparisons. QLS, Quality of Life Scale (higher scores
mean better quality of life).
Overall, our profiles reflected a continuum in adaptation to CFS. In particular, the Sympathetic
with dysautonomia and Balanced profiles showed the lowest and highest quality of life, respectively;
mean difference (95% Confidence interval) was 9.0 (2.8 to 15.2). Although t e were not significantly
different from the other profiles, quality of life seemed to be intermediate in the Parasympathetic and
Sympathetic profiles. Effect sizes of the mean differences between the Sympathetic with dysautonomia
and Balanced profiles were large; Cohen’s d (95% Confidence interval) was 0.8 (0.2 to 1.4).
4. Discussion
The autonomic nervous system may play role in many systemic diseases and there is growing
evidence of autonomic dysfunction in CFS patients. The present study provided an understanding of
CFS heterogeneity by including fatigue severity, autonomic symptoms and arterial stiffness measured
by objective or/and subjective assessments, in a cohort of CFS patients that fulfil the Fukuda criteria.
Four profiles emerged: sympathetic with dysautonomia, sympathetic, parasympathetic and balance.
We found that autonomic phenotypes in CFS patients were strongly associated with measures of illness
severity (measured by fatigue severity), suggesting, as there is limited evidence for the benefits of
any treatment in CFS, that different approaches to treatment might be warranted. The sympathetic
with dysautonomia subtype was distinguished by (1) more frequent postexertional malaise than
other subtypes, (2) more severe disease expressed by high value of fatigue scales, (3) most frequently
reported greater subjective autonomic symptoms with sympathetic over-modulation and (4) the lowest
quality of life. Additionally, those characterized by the parasympathetic profile were at higher risk of
fatigue. Patients in the sympathetic subtype were (1) the oldest, (2) at lower risk of fatigue, (3) reported
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the least subjective autonomic symptoms with sympathetic over-modulation and (4) had the highest
value of arterial stiffness. Patients in the balance subtype were (1) the youngest, (2) at lower risk of
fatigue, (3) in sympathovagal balance, (4) had the highest quality of life and (5) had the lowest value of
arterial stiffness.
Previous research has reported that the most common dysautonomia symptoms in CFS are
dizziness, orthostatic intolerance, palpitation, syncope, postural orthostatic tachycardia syndrome,
urinary frequency and nocturia. Castro-Marrero et al. have shown that the most important autonomic
symptoms in a CFS Spanish population are dizziness or cephalic instability (83.2%), episodes of
orthostatic hypotension (78.8%) and motor in coordination with or without falls (76.6%) [23]. Maclachlan
et al. used non-invasive autonomic measurement (Task Force® Monitor) to examine whether current
CFS diagnostic criteria are identifying different phenotypes of this condition. In subjects meeting
different CFS criteria (Fukuda + Canadian consensus 2003, Fukuda + Canadian consensus 2003 +
Canadian consensus 2011), they concluded that changes in autonomic function appear to take the form
of an initial sympathetic hyperactivity followed in more severe disease by sympathetic underactivity
and increased parasympathetic modulation. Moreover, the authors suggest that CFS subjects reported
significantly greater autonomic impairment compared to sedentary controls. Despite that findings did
not show significant objective autonomic differences, the authors raised questions about the role of
co-morbid depression and sedentary controls and they indicated that more consistent inclusion and
exclusion criteria across studies is necessary to understand CFS pathophysiology [24].
Our results confirm that continuous stress might result in a deregulation of autonomic nervous
system manifested by sympathetic hyperactivity (sympathetic with dysautonomia profile) or
sympathetic underactivity (parasympathetic profile). In our opinion, the lack of uniformity in
the currently available literature regarding autonomic functioning in those with CFS may be, at least in
part, related to the heterogeneity within CFS cohorts, various inclusion criteria, recruitment strategies,
case ascertainment methods, degrees of psychiatric comorbidity and sociodemographic and biologic
characteristics or various protocols for autonomic testing. One of our study strengths was the
comprehensive nature of both the recruitment process and the characterization of the cohort using
subjective and objective measures of disease severity and autonomic dysfunction. Our study also
highlights the theory that abnormalities in the function of the autonomic nervous system are an
important factor for better understanding CFS pathophysiology.
Other phenotypes in CFS patients have been investigated in several studies. Aslakson et al.
classified CFS heterogeneity including: a polysymptomatic profile, a sore throat or painful lymph node
profile, phenotypes according to the presence or absence of musculoskeletal pain [25]. Collin et al.
showed that post-exertional malaise, cognitive dysfunction and unrefreshing sleep were cardinal
symptoms. Muscle and joint pain, headache, sore throat and painful lymph nodes delineated three
phenotypes: polysymptomatic, oligosymptomatic and pain only—these phenotypes were associated
with sex, duration of illness and comorbidity [26]. Wilson et al. reported two clinically important
profiles of CFS patients. Patients with profile one (68% sample) were younger, had a shorter duration of
illness, lower female to male ratio, were less premorbid, had current and familial psychiatric morbidity
and less functional disability. Profile two consisting of 32% of the total sample was characterized by a
wider variety of symptom reports, longer duration of illness, higher female:male ratio, more functional
disability, more medical visitation, more depression and anxiety [27].
Janal et al. shows that in 161 women meeting Fukuda criteria for CFS, principal components analysis
of the 10 ‘minor’ symptoms of CFS produced three factors interpreted to indicate musculoskeletal, infectious
and neurological subtypes. Patients in the neurological profile were at increased risk for reduced cognitive
function (attention, working memory, long-term memory or rapid performance) and reduced physical ability.
Those characterized by the musculoskeletal profile were at increased risk for the diagnosis of fibromyalgia
and reduced physical function. Patients in the infectious subtype were at lower risk for evidence co-occurring
fibromyalgia, and showed lesser risk of functional impairment [28]. Jason et al. suggest that subtyping
individuals with CFS on sociodemographic (gender, age and socioeconomic status), functional disability,
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viral, immune, neuroendocrine, neurology, autonomic and genetic biomarkers can provide clarification for
researchers and clinicians who encounter CFS’ characteristically confusing heterogeneous symptom profiles.
Subgrouping is the key to understanding how CFS begins and how it is maintained, how medical and
psychological variables influence its course and how it can be prevented and treated [29].
The importance of the parameters describing the arterial function (stiffness) has been shown on
different groups of patients: end-stage renal disease, coronary artery disease, hypertension, diabetes
and the general healthy population. A stiffer arterial system is accompanied by impaired cerebral
autoregulation. Thus, hypotensive episodes occurring in the context of a stiffer arterial system may
potentiate the risk of brain hypoperfusion and, consequently, of cognitive dysfunction [30,31]. There are
only a limited number of studies on the effect of CFS on arterial function in this condition. Studies
using pulse wave analysis have suggested that arterial stiffness may be a problem in those with CFS
and could represent a marker of enhanced cardiovascular risk in this patient group [32].
In the above study, both physical and mental fatigue factors measured by CFQ scale were related
to aortic stiffness. We found that arterial stiffness parameters are related to fatigue severity measured
by Chalder Fatigue Scale_mental domain, Fatigue Severity Scale and Fatigue Impact Scale. Higher FIS
and lower FSS scores were related to lower aortic stiffness. In a study published in 2008 [33], aortic
stiffness was higher in CFS patients compared to healthy controls. In line with some results from
the above study, higher elasticity of the large artery was correlated with lower subjective fatigue at
rest in older woman [34]. Therefore, further studies should include Aortic stiffness assessment in
CFS patients.
This study has shown that patients in the sympathetic subtype had the highest value of arterial
stiffness compared to patients in the balance subtype, which had the lowest value of arterial stiffness.
Arterial stiffness, an important marker of cardiovascular risk, is an independent predictor of all-cause
cardiovascular morbidity and mortality. However, the impact of transient elevations in sympathetic
nervous system activity on the large elastic arteries such as aorta and carotid arteries are ambiguous [35].
Swierblewska et al. showed that a chronic increase in sympathetic nervous system activity was positively
correlated with higher carotid-femoral pulse wave velocity in healthy men but it was independent
of age, BMI, waist circumference, waist-to-hip ratio, heart rate, pulse pressure or blood pressure [36].
In contrast, acute experimental increases in sympathetic activity in the absence of increases in BP
resulted in no changes in aortic or carotid elastic compliance in young healthy humans, suggesting a
rise in blood pressure is necessary to alter elastic artery stiffness [34]. Pierce suggested that additional
studies are needed, but outcomes may differ based on the study protocol; namely, the method of
measuring stiffness (e.g., carotid-femoral pulse wave velocity vs. local compliance), whether elevated
baseline sympathetic activity is present and differences in sex, age and clinical characteristics of the
participants [35]. Moreover, as one of the main underlying mechanisms of arterial stiffness is arterial
fibrosis, a number of studies have focused on absolute collagen content and concentration. Collagen
accumulates in the aorta with age and comorbidities such as hypertension or diabetes [37]. Alterations
in the proportions of arterial collagen types, excessive intramural build-up of other proteins, such as
integrins, fibronectin and desmin, may affect structural changes in the vessel wall that occur with vessel
stiffening [37]. Future research might focus on the observation that collagen cross linking disorders
such as Ehlers danlos and marfan syndromes are recognized in association with CFS which may
influence the measurement of arterial stiffness.
One limitation of this study was the relatively small study population of CFS subjects. However,
conducting clinical research in this group presents challenges in recruiting and studying a fully
characterized cohort. Another limitation was that there was no specific questionnaire to measure
post-exertional malaise, a core symptom of CFS. Future research is needed to determine whether
the effectiveness of investigation is different across CFS phenotypes. Our next step will be to design
profile-specific treatment intervention to investigate association between autonomic phenotypes in
CFS patients and specific treatment outcomes in longitudinal studies.
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5. Conclusions
The main implications of our study are: (a) identifying autonomic symptomatology in patients
with CFS will contribute to the understanding of the role that the autonomic nervous system plays
in CFS pathophysiology (b) subjective and/or objective autonomic function measurement should be
required during the diagnostic process (c) autonomic phenotypes in CFS patients are strongly associate
with measures of illness severity, suggesting that different approaches to treatment might be warranted.
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Appendix A
Table A1. Detailed clinical characteristics of each profile.
Parameters Sympatheticwith ANS Sympathetic Parasympathetic Balanced
Mean SD Mean SD Mean SD Mean SD
COMPASS 31
Orthostatic intolerance 16.1 11.6 7.2 12.1 9.9 12.2 9.8 8.9
Vasomotor 0.8 1.4 0.0 0.0 1.1 1.6 0.8 1.4
Secretomotor 7.0 3.8 2.1 3.7 3.9 3.8 5.6 3.5
Gastrointestinal 5.6 3.7 3.9 4.1 3.7 3.9 5.4 4.6
Bladder 0.6 0.9 0.0 0.0 0.7 1.2 0.5 0.8
Pupillomotor 1.7 1.4 0.8 1.1 1.0 0.9 0.8 1.0
CompassTotal 31.9 13.7 14.1 17.6 20.3 14.8 22.8 13.1
Arterial stiffness
PWVaortic 8.2 1.3 13.8 1.0 8.5 1.2 7.8 1.1
Aixaortic 24.3 12.7 57.2 2.8 39.2 14.7 24.1 9.9
SBPaortic 126.3 15.2 153.5 14.5 140.0 13.7 125.5 16.2
Autonomic parameters
LFnu_RRI 62.9 12.6 53.9 21.6 48.9 16.0 51.4 17.4
HFnu_RRI 37.1 12.6 46.1 21.6 51.1 16.0 48.6 17.4
LF-RRI 807.8 1111.6 429.2 644.4 461.6 429.2 520.9 503.8
HF-RRI 499.7 818.9 159.1 94.3 502.6 580.0 591.3 767.8
PSD-RRI 1673.1 2277.0 786.7 930.7 1251.3 1143.2 1468.9 1484.3
LF/HF-RRI 2.5 2.9 1.9 1.9 1.3 1.1 1.5 1.3
LF/HF 2.3 1.9 1.6 1.0 0.9 0.5 1.2 0.8
LFnu-dBP 64.2 8.8 59.3 14.3 37.3 11.9 48.2 11.2
HFnu-dBP 9.9 6.1 7.8 3.0 16.6 14.0 14.1 9.5
LF-dBP 10.5 11.5 4.6 3.1 4.1 3.8 4.9 8.3
HF-dBP 1.3 1.5 0.5 0.4 1.8 2.9 1.4 2.5
PSD-dBP 15.9 16.5 7.3 3.8 12.8 12.4 10.0 15.1
LFnu_sBP 52.8 10.1 50.6 10.4 30.0 12.5 38.0 10.7
HFnu_sBP 14.6 8.6 11.7 4.7 16.1 11.4 16.4 11.7
LF-sBP 10.1 12.9 6.8 1.9 7.3 10.1 6.2 7.0
HF-sBP 2.5 2.9 1.5 0.6 2.6 2.4 2.6 4.8
PSD-sBP 19.8 26.9 14.0 4.4 29.4 49.6 17.1 17.4
LF/HF 1.8 1.4 1.5 1.1 0.7 0.5 1.0 0.6
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